Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

DiaMedica Therapeutics (DMAC) Invested Capital (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Invested Capital readings, the most recent being $47.2 million for Q1 2026.

  • Quarterly Invested Capital rose 39.11% to $47.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.2 million through Mar 2026, up 39.11% year-over-year, with the annual reading at $56.1 million for FY2025, 37.8% up from the prior year.
  • Invested Capital hit $47.2 million in Q1 2026 for DiaMedica Therapeutics, down from $56.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $59.7 million in Q2 2023 and bottomed at $27.0 million in Q1 2023.
  • Average Invested Capital over 5 years is $43.7 million, with a median of $46.3 million recorded in 2024.
  • The largest annual shift saw Invested Capital surged 85.62% in 2022 before it tumbled 49.13% in 2025.
  • DiaMedica Therapeutics' Invested Capital stood at $31.8 million in 2022, then surged by 60.42% to $51.1 million in 2023, then dropped by 20.25% to $40.7 million in 2024, then skyrocketed by 37.8% to $56.1 million in 2025, then dropped by 15.82% to $47.2 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Invested Capital are $47.2 million (Q1 2026), $56.1 million (Q4 2025), and $51.6 million (Q3 2025).